Rani Therapeutics

Rani Therapeutics is a clinical-stage biopharmaceutical company that has developed a disruptive technology for the oral delivery of biologics including peptides, proteins and antibodies.

 

Rani Therapeutics was founded in 2012 by Mir Imran. The company is headquartered in San Jose, California.

Rani Therapeutics' platform technology converts injectable drugs like PTH and adalimumab into pills.

Rani Therapeutics has developed the RaniPill™ robotic pill, an oral biologics platform designed to replace injectable biologics. The RaniPill™ is a pain-free alternative for subcutaneous injections, eliminating one of the biggest obstacles to patient compliance.

 

Rani has a strong patent position with more than 280 patents filed. The research and technology behind Rani Therapeutics came out of InCube Labs, a multi-disciplinary life sciences R&D lab focused on breakthrough medical innovations.

 

Rani is backed by GV, Novartis, Takeda, Astra Zeneca, Crystal Horizon Investments, Pinemount Investment, Pacific Ventures and others. The company raised $69M in Series E round on Dec 10, 2020. This brings Rani's total funding to $211.5M to date.

 

 

  • Year founded: 2012
  • Funding Info: $211.5M over 6 Rounds (Latest Funding Type: Series E)
  • Yearly Revenue: NA
  • Employee Size: 51-200
  • Business Valuation: NA
  • City/Town: San Jose
  • State: California
  • Country: United States
Related businesses